Interim report May - July 2008/09

Interim report May - July 2008/09 

•	Order bookings rose 9* percent. Order backlog at an all time high level of SEK
5,229 M.
•	Net sales amounted to SEK 1,025 M, an increase by 13* percent.
•	Operating profit amounted to SEK 13 M (36), due to a scheduled low volume of
deliveries. 
•	Profit after taxes amounted to SEK 1 M (20). 
•	Earnings per share after dilution was SEK 0.02 (0.22).
•	Cash flow from operating activities was negative SEK 163 M (neg. 28) due to
seasonal build-up of working capital. 
•	Elekta reiterates the outlook of a net sales growth of over 15 percent in
local currency and operating profit growth of over 15 percent for the full year
2008/09. 

* Compared to the first quarter last fiscal year at unchanged exchange rates. 


President Tomas Puusepp comments 

Demand for Elekta's clinical solutions, products and services remains strong. 
Elekta continues to strengthen its market share and the product portfolio is
more competitive than ever before.

Important when assessing Elekta's development, order bookings on a rolling
twelve-month basis increased by 12 percent, despite a negative currency effect. 

During the first quarter our major efforts were to integrate CMS' organization
and offering with Elekta's other software solutions. Elekta's software systems
support the entire workflow in cancer treatment, from diagnosis to dose
planning, treatment, administration and follow-up. For the present fiscal year,
CMS adds to net sales, but contributes only marginally to op-erating profit. 

Elekta will strengthen its position in emerging markets. Our own office in
Brazil was up and running by May 1 and Latin America will be an important growth
market for Elekta going forward. We will also continue to invest substantially
in R&D, with the aim of improving quality and cost-efficiency in cancer care and
management of brain disorders. 

The introduction of Elekta VMAT has created a good momentum in the market place
and we see a continued positive trend for business area oncology systems going
forward, even if the competition in this segment is high. Another growth driver
in a mid-term perspective is the possibility to market Elekta Compact™ in
markets in need of rapid build-up of care capacity.   

The interest for Leksell Gamma Knife® Perfexion™ remains strong. During the
first quarter  Leksell Gamma Knife® Perfexion™ systems were delivered to Korea
and Japan . We also see high interest in Elekta Axesse™, our fully integrated
system for stereotactic radiation therapy. 

After we communicated the full year outlook for 2008/09, particularly the US
dollar has developed favorably for Elekta. Provided that today's currency rates
remain for the full year, the positive effect on Elekta's earnings will be
significant from the third quarter and onwards.  

As an effect of a scheduled low level of delivery volumes the first quarter's
operating profit was weak. However, we reiterate the previously communicated
outlook for 2008/09. Net sales and operating profit will be significantly higher
in the second half of the fiscal year, compared with the first.


Tomas Puusepp
President and CEO


For further information, please contact:

Tomas Puusepp, President and CEO, Elekta AB (publ)
Tel: +46 8 587 25 520, e-mail: tomas.puusepp@elekta.com

Håkan Bergström, CFO, Elekta AB (publ)
Tel: +46 8 587 25 547, e-mail: hakan.bergstrom@elekta.com 

Lena Schattauer, Investor Relations, Elekta AB (publ)
Tel: +46 8 587 25 722, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com 


About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools for radiation therapy and radiosurgery as
well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.